Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/wiley/news-tdWeVtPm0i
References (0)
References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.
- Publisher
- Wiley
- Copyright
- Journal compilation © 2009 Blackwell Publishing Ltd
- ISSN
- 0961-5423
- eISSN
- 1365-2354
- DOI
- 10.1111/j.1365-2354.2008.01077.x
- Publisher site
- See Article on Publisher Site
Abstract
BREAKTHROUGH IN THE TREATMENT OF GLIOBLASTOMA SEEN IN THE LABORATORY A new drug product known at the present time only as ANG1005 has been found to successfully cross the blood–brain barrier with 100‐fold higher transport rate compared with drugs like Paclitaxel, which is normally prevented from reaching the brain by the P‐glycoprotein efflux pump. This new drug product also crosses the blood–brain barrier with a 10‐fold higher transport rate than Temosolomide. When the drug was given to mice with the type of brain tumour known as glioblastoma, the mice had a significantly important 27% increased survival. A second study, led by Dr Francis Bichat, head of the scientific platform at Oncodesign in Dijon, France, evaluated the anti‐cancer properties of the drug in cancer cell lines and mice, as well as investigating its toxicity and what happened to the drug in mice. The French team found that ANG1005 had the same anti‐cancer properties as did Paclitaxel in cancer cell lines. Speaking at a recent international cancer conference, Dr Bichat stressed that the anti‐tumour activity of Paclitaxel was maintained when given alongside ANG1005 and absolutely no loss of drug activity was seen. He also found a significant inhibition of brain
Journal
European Journal of Cancer Care – Wiley
Published: Jan 1, 2009